---
layout: post
title: "Prospective Grant of Exclusive Patent License: Development of RegulatoryT-Cell Therapies for the Treatment of Hemophilia A (HA)"
date: 2026-02-05 19:08:09 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-00721
original_published: 2020-01-17 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of Exclusive Patent License: Development of RegulatoryT-Cell Therapies for the Treatment of Hemophilia A (HA)

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 17, 2020 00:00 UTC
**Document Number:** 2020-00721

## Summary

The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to TeraImmune, Inc. ("TeraImmune") located in Rockville, Maryland.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/17/2020-00721/prospective-grant-of-exclusive-patent-license-development-of-regulatoryt-cell-therapies-for-the)
- API: https://www.federalregister.gov/api/v1/documents/2020-00721

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
